Noradrenaline Aguettant (Noradrenaline Tartrate)

Noradrenaline Tartrate acts as a direct agonist at alpha‑1 adrenergic receptors, causing vasoconstriction and raising systemic vascular resistance. It also stimulates beta‑1 receptors modestly, which can increase heart rate and contractility, together improving arterial pressure and tissue perfusion.

The dosing regimen for Noradrenaline Aguettant is individualized and determined by the prescribing clinician based on the patient’s hemodynamic status, response, and clinical setting. Healthcare professionals adjust the infusion rate to achieve target blood pressure goals.

Safety data for Noradrenaline Tartrate in pregnancy and lactation are limited. Use is generally reserved for situations where the potential benefit to the mother outweighs any possible risk to the fetus or infant, and decisions are made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Noradrenaline is often preferred over dopamine because it provides more predictable vasoconstriction with less tachycardia. Compared with epinephrine, it has a stronger α‑adrenergic effect and a weaker β‑adrenergic effect, making it suitable for raising blood pressure without excessive heart rate increase.

The product should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen. Prior to use, inspect the solution for particulate matter or discoloration, and handle with aseptic technique to avoid contamination.

Noradrenaline Aguettant is given as an intravenous infusion, typically through a central venous catheter to reduce the risk of extravasation. The infusion rate is titrated by the clinician to achieve the desired blood pressure response, with continuous monitoring.

Serious risks include severe hypertension, myocardial ischemia, life‑threatening arrhythmias, and tissue necrosis if the drug extravasates from the vein. Prompt recognition and management of these events are essential during therapy.

Patients with known hypersensitivity to noradrenaline or any formulation component should avoid the drug. Caution is advised in individuals with uncontrolled hypertension, severe cardiac disease, or peripheral vascular disorders where further vasoconstriction could be harmful.